Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 60

Results For "ANDA"

2464 News Found

Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr
News | May 18, 2025

Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr

The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025


Sanofi India posts 27% growth in operating profits in Q1 2025
News | May 16, 2025

Sanofi India posts 27% growth in operating profits in Q1 2025

Standalone profit from operations for the quarter were Rs. 162 crores


Remedium Lifecare secures Rs. 182.7 crore export deal
News | May 16, 2025

Remedium Lifecare secures Rs. 182.7 crore export deal

The CDMO upgrade represents a transformational step for Remedium Lifecare


Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection
Drug Approval | May 14, 2025

Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection

Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy


Borealis advancing sustainability medical devices with the Bornewables
Sustainability | May 13, 2025

Borealis advancing sustainability medical devices with the Bornewables

The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices


Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr
News | May 12, 2025

Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr

The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025


Zydus receives final approval from USFDA for Glatiramer Acetate Injection
Drug Approval | May 12, 2025

Zydus receives final approval from USFDA for Glatiramer Acetate Injection

Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes


Lupin launches Eslicarbazepine Acetate tablets in US
Drug Approval | May 08, 2025

Lupin launches Eslicarbazepine Acetate tablets in US

Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity


Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM
News | May 08, 2025

Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM

The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets